Company Overview and News

1
Brian Gaynor: Week brings bad news for the NZX

2018-04-13 nzherald.co.nz
It hasn't been a great week for the NZX, with the delisting of Trilogy International, Happy Valley Milk's decision to list on the ASX and Icebreaker's confirmed purchase price by US apparel giant VF Corp when an NZX listing was a potential alternative.
Upvote Downvote

1
'Great shame' if Fletcher sold and delisted from NZX, says investment chief

2018-04-13 nzherald.co.nz
New Zealand investors would be much the poorer if Fletcher Building left the NZX, an investment expert said, and although the firm had issues, he does not want to see it follow a string of other businesses leaving our sharemarket.
Upvote Downvote

 
Shares keep falling amid global sell-off

2018-03-26 nzherald.co.nz
New Zealand's S&P/NZX 50 Index fell about 1 per cent for the second straight session, joining a global selloff that started on Wall Street and extended into Asia amid fears of a trade war. Spark NZ, Air New Zealand, Sky Network Television and A2 Milk all fell.
Upvote Downvote

 
MARKET CLOSE: NZ shares join global sell-off

2018-03-26 nbr.co.nz
(BusinessDesk) - New Zealand's S&P/NZX 50 Index fell about 1 percent for the second straight session, joining a global selloff that started on Wall Street and extended into Asia amid fears of a trade war. Spark NZ, Air New Zealand, Sky Network Television and A2 Milk all fell.
Upvote Downvote

 
MARKET CLOSE: NZ shares drop 1% on global selloff, US stocks wobble as Trump backs down on spending bill

2018-03-23 nbr.co.nz
New Zealand's NZX 50 Index dropped nearly 1 percent on global trade news in Friday trading., with Synlait Milk and Sky Network Television suffering while CBL remained in a trading halt as its administrators gained more time to consider its finances.
Upvote Downvote

 
Shares drop 1% on global selloff, led by Synlait, Sky TV

2018-03-23 nzherald.co.nz
New Zealand's NZX 50 Index dropped nearly 1 per cent on global trade news, with Synlait Milk and Sky Network Television suffering while CBL remained in a trading halt as its administrators gained more time to consider its finances.
Upvote Downvote

 
Synlait Milk drives sharemarket to record high

2018-03-21 nzherald.co.nz
New Zealand's S&P/NZX 50 Index rose to a record led by Synlait Milk, which jumped to an all-time high after posting strong first-half earnings growth. Synlait's partner A2 Milk Co also gained, along with Kathmandu Holdings and the Fonterra Shareholders' Fund.
Upvote Downvote

 
MARKET CLOSE: NZX 50 rises to record; Synlait jumps to all-time high

2018-03-21 nbr.co.nz
(BusinessDesk) - New Zealand's S&P/NZX 50 Index rose to a record led by Synlait Milk, which jumped to an all-time high after posting strong first-half earnings growth. Synlait's partner A2 Milk Co also gained, along with Kathmandu Holdings and the Fonterra Shareholders' Fund.
Upvote Downvote

 
Coles spin-off lifts ASX to flat finish for the week

2018-03-16 theage.com.au
Wesfarmers' decision to spin-off Coles lifted equities on Friday and trimmed the Australian sharemarket's loss this week to 0.2 per cent, defying weakness across Asia.
Upvote Downvote

 
Coles spin-off lifts ASX to flat finish for the week

2018-03-16 smh.com.au
Wesfarmers' decision to spin-off Coles lifted equities on Friday and trimmed the Australian sharemarket's loss this week to 0.2 per cent, defying weakness across Asia.
Upvote Downvote

 
Markets Live: Myer out of ASX200

2018-03-11 smh.com.au
Australian equities finished a week of simmering trade tensions and the exit of Donald Trump's top economic adviser 0.6 per cent higher as markets warmed to the view the White House is backing down from starting an outright trade war.
Upvote Downvote

 
Trade relief spurs ASX to weekly gain

2018-03-11 smh.com.au
Australian equities finished a week of simmering trade tensions and the exit of Donald Trump's top economic adviser 0.6 per cent higher as markets warmed to the view the White House is backing down from starting an outright trade war.
Upvote Downvote

 
MARKET CLOSE: NZ shares rise; Metro Glass rebounds ahead of index exit, Comvita falls

2018-03-09 nbr.co.nz
New Zealand shares rose, led higher by a rebounding Metro Performance Glass. Spark New Zealand gained while Comvita fell.
Upvote Downvote

 
Brian Gaynor: New Xero boss has other fish to fry

2018-03-09 nzherald.co.nz
Rod Drury's resignation as Xero's chief executive this week was a huge surprise, as was the appointment of outsider Steve Vamos to replacement him.
Upvote Downvote

 
Trade relief spurs ASX to weekly gain

2018-03-09 theage.com.au
Australian equities finished a week of simmering trade tensions and the exit of Donald Trump's top economic adviser 0.6 per cent higher as markets warmed to the view the White House is backing down from starting an outright trade war.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 629506106